TELA Bio (NASDAQ:TELA) Stock Moved Up to “Hold” by Wall Street Zen

TELA Bio (NASDAQ:TELA – Get Free Report) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other brokerages also recently weighed in on TELA. Weiss Ratings upgraded shares of TELA Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, October 26th. Craig Hallum initiated coverage on shares of TELA Bio in a research report on Friday, September 25th. They issued a “buy” rating and a $2.00 target price on the stock. Finally, UBS Group set a $2.00 price target on shares of TELA Bio in a research note on Friday, September 25th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, TELA Bio currently has an average rating of “Moderate Buy” and an average price target of $2.14.

Read Our Latest Report on TELA

TELA Bio Stock Performance

TELA stock opened at $0.82 on Friday. The business has a 50 day moving average price of $1.03 and a 200 day moving average price of $0.85. TELA Bio has a fifty-two week low of $0.50 and a fifty-two week high of $1.50.

TELA Bio (NASDAQ:TELA – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.03. TELA Bio had a negative net margin of 53.57% and a negative return on equity of 1,320.81%. The company had revenue of $18.96 million for the quarter, compared to analyst estimates of $20.00 million. Analysts forecast that TELA Bio will post -0.70 EPS for the current fiscal year.

Insider Activity

In other news, Director Joseph Capper bought 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The stock was purchased at an average cost of $1.22 per share, with a total value of $30,500.00. Following the transaction, the director directly owned 179,827 shares in the company, valued at $219,388.94. This trade represents a 16.15% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders bought 100,000 shares of company stock valued at $109,000. 1.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On TELA Bio

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TELA. Rollins Financial Advisors LLC acquired a new stake in shares of TELA Bio in the third quarter valued at approximately $33,000. StoneX Group Inc. purchased a new position in shares of TELA Bio during the third quarter worth approximately $34,000. Wavvest Wealth LLC purchased a new position in shares of TELA Bio during the third quarter worth approximately $96,000. UP Strategic Wealth Investment Advisors LLC acquired a new position in shares of TELA Bio in the 2nd quarter valued at $91,000. Finally, Marshall Wace LLP acquired a new position in shares of TELA Bio in the 3rd quarter valued at $141,000. Hedge funds and other institutional investors own 94.35% of the company’s stock.

TELA Bio Company Profile

(Get Free Report)

TELA Bio, Inc. is a medical technology company that develops and commercializes advanced tissue-reinforcement products for soft-tissue repair and reconstruction. The company’s products are designed to support the repair of damaged or weakened tissue while preserving a more natural tissue response. TELA Bio’s principal product platform is OviTex Reinforced Tissue Matrix, which combines biologic tissue with polymer reinforcement in a proprietary, textile-like design. OviTex products are used in procedures involving hernia and abdominal wall repair, as well as other soft-tissue reconstruction applications.

Recommended Stories

Analyst Recommendations for TELA Bio (NASDAQ:TELA)

Receive News & Ratings for TELA Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TELA Bio and related companies with MarketBeat.com's FREE daily email newsletter.